Lifeward

Company Overview

Snapshot

Founded in June 2001, Lifeward operates with 11–50 employees. The company has raised a total of $249.72 million across 20 funding rounds from 11 investors. Lifeward went public on NASDAQ in September 2014, raising $36 million in its Initial Public Offering.

Business overview

Lifeward is dedicated to innovating solutions that enhance the lives of individuals with physical limitations or disabilities. The company's core technology revolves around wearable robotic exoskeletons for walking, which are designed to empower users to regain mobility. Lifeward's product portfolio includes the ReWalk Exoskeleton, ReStore Exo-Suit.

Strategic signal

In November 2023, Medicare proposed a preliminary reimbursement level for the ReWalk Personal Exoskeleton, a historic move that signals significant progress towards broader accessibility and affordability for users. This development is crucial for Lifeward, as it indicates a potential expansion of market reach and a stronger financial outlook, validating the long-term viability and impact of its assistive technologies within the healthcare system.

Company Intelligence Q&A

What was a significant recent development regarding Medicare coverage for Lifeward's products?

In November 2023, Medicare proposed a preliminary reimbursement level for the ReWalk Personal Exoskeleton, marking a historic step towards facilitating access to the device.

When did Lifeward go public and on which exchange?

Lifeward went public on NASDAQ in September 2014, raising $36 million in its Initial Public Offering.

What was a key acquisition made by Lifeward?

In August 2023, Lifeward acquired AlterG, a move aimed at enhancing its product portfolio and driving profitability.

What was a notable product milestone achieved by the company in 2018?

In November 2018, ReWalk announced the placement of its 500th exoskeleton system, demonstrating significant adoption of its technology.

What was a significant regulatory achievement for ReWalk's ReBoot Soft Exo-Suit?

In November 2021, the FDA designated ReWalk's ReBoot Soft Exo-Suit as a Breakthrough Device, recognizing its potential to provide more effective treatment for life-threatening or irreversibly debilitating diseases or conditions.